Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021)

Nautilus Biotechnology's (NAUT) quarterly Non Operating Investment Income came in at $10982.0 in Q1 2021, down 79.26% quarter-over-quarter from $52952.0 in Q4 2020.

Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has disclosed Non Operating Investment Income across 2 years of filings, most recently posting $10982.0 for Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 235,807.00
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - 230,000.00
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 Nautilus Biotechnology 289.99 Mn 194.12 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 10,982.00
Mar 31, 2021 10,982.00
Dec 31, 2020 52,952.00
Dec 31, 2020 52,952.00
Sep 30, 2020 15,680.00
Sep 30, 2020 15,680.00